The global industry for Behçet's disease therapeutics is witnessing a period of significant growth, driven by an increasing prevalence of the disease and advancements in treatment options. The requirement for effective therapies to manage the varying symptoms of Behçet's disease is stimulating this development. Pharmaceutical companies are active